Paradigm Biopharmaceuticals Limited

Equities

PAR

AU000000PAR5

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 02:10:52 2024-06-17 am EDT			5-day change	1st Jan Change
0.235 ^AUD	0.00%		-4.08%	-44.71%

Apr. 19	Paradigm Biopharmaceuticals Submits Documents to FDA for Phase 3 Osteoarthritis Program	MT
Feb. 28	Paradigm Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

Paradigm Biopharmaceuticals Limited Announces Resignation of Chris Fullerton as Non- Executive Director

November 19, 2020 at 04:14 pm EST

Paradigm Biopharmaceuticals Ltd. announced Non- Executive Director, Mr. Chris Fullerton has tendered his resignation to the Paradigm board. Chris had joined the Paradigm Board prior to its IPO/ASX listing and made strong contributions to the company's development and success.

Latest news about Paradigm Biopharmaceuticals Limited

Paradigm Biopharmaceuticals Submits Documents to FDA for Phase 3 Osteoarthritis Program	Apr. 18	MT
Paradigm Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 27	CI
Paradigm Biopharma's Injectable Pentosan Polysulfate Sodium Trial Reaches Endpoint	Feb. 12	MT
Paradigm Biopharmaceuticals Secures AU$7 Million R&D Tax Incentive Rebate for Fiscal Year 2023; Shares Rally 9%	Feb. 06	MT
Paradigm Biopharmaceuticals Opens Retail Entitlement Offer	Nov. 06	MT
Paradigm Biopharmaceuticals Raising AU$30 Million for Clinical Trial	23-10-30	MT
Paradigm Biopharmaceuticals Ltd Announces Resignation of John Gaffney as Independent Non Executive Director, Effective Immediately	23-10-20	CI
Paradigm Biopharmaceuticals Validates Cartilage Preservation in Knee Osteoarthritis Trial	23-10-18	MT
Paradigm Biopharmaceuticals Confirms Effectivity of Pain Medication in Osteoarthritis Trial	23-10-10	MT
Paradigm Biopharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-25	CI
Paradigm Biopharmaceuticals Validates Efficacy of Anti-Inflammatory Medication in Canine Trial	23-06-02	MT
Paradigm Biopharmaceuticals Announces Phase 2 Trial in Osteoarthritis Shows Signs of Disease Modification At 6-Month Follow-Up	23-04-11	CI
Paradigm Biopharmaceuticals Limited Announces Injectable PPS Demonstrates Multiple Signals of A DMOAD in PARA_OA_008 Phase 2 Clinical Study	23-04-03	CI
Paradigm Biopharmaceuticals Secures European Ethics Approval for Knee Osteoarthritis Trial	23-03-14	MT
Paradigm Biopharmaceuticals Ltd Receives European Regulatory and Ethics Approval for the Pivotal PARA_OA_002 Global Clinical Trial	23-03-13	CI
Starpharma Appoints CFO	23-03-03	MT
Paradigm Biopharmaceuticals Names Interim CFO	23-03-02	MT
Paradigm Biopharmaceuticals Limited Announces the Change of Chief Financial Officer	23-03-02	CI
Paradigm Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-26	CI
Lingering Concerns on Economic Outlook, Rate Hikes Dampen Appetite for Australian Shares	22-12-28	MT
Paradigm Biopharmaceuticals Secures Go-Signal to Advance Phase 3 Osteoarthritis Trial	22-12-28	MT
Paradigm Biopharmaceuticals Ltd Advises the First Safety Review Meeting of the Data Monitoring Committee for the Pivotal Para_OA_002 Clinical Trial	22-12-27	CI
Paradigm Biopharmaceuticals Moves Closer to US Patent Approval for Bone Marrow Treatment	22-12-12	MT
Paradigm Biopharmaceuticals CEO to Step Down; Shares Fall 11%	22-11-21	MT
Paradigm Biopharmaceuticals Limited Announces Executive Changes	22-11-21	CI

Chart Paradigm Biopharmaceuticals Limited

Duration

Period

Chart Paradigm Biopharmaceuticals Limited

More charts

Company Profile

Paradigm Biopharmaceuticals Limited is a late-stage drug development company. The Company is engaged in discovering, developing, and delivering pharmaceutical therapies. It is focused on the development of injectable pentosan polysulfate sodium (iPPS/PPS) for the treatment of osteoarthritis (OA) and mucopolysaccharidosis (MPS). Pentosan polysulfate sodium is a semi-synthetic drug manufactured from the wood chips of European beech trees. Extracted glucurono-xylans are sulfated to produce a negatively charged product that mimics glycosaminoglycans (GAGs). It develops PPS under the brand name Zilosul. PPS also inhibits the synthesis of the metalloproteinase, MMP-3 (Troeberg) involved in degrading cartilage. PPS also include treatment of joint function, mobility, and pain in patients with MPS; treating alphavirus-induced arthralgia (such as Ross River virus and Chikungunya); chronic heart failure (HF) and acute respiratory distress syndrome (ARDS).

Sector

Biotechnology & Medical Research

Calendar

2024-08-22 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.235 AUD

Average target price

0.47 AUD

Spread / Average Target

+100.00%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PARADIGM BIOPHARMACEUTICALS LIMITED	-44.71%	54.44M
MODERNA, INC.	+39.86%	53.67B
LONZA GROUP AG	+33.67%	38.86B
IQVIA HOLDINGS INC.	-8.26%	38.76B
CELLTRION, INC.	-10.77%	27.27B
ICON PUBLIC LIMITED COMPANY	+11.60%	25.91B
ALNYLAM PHARMACEUTICALS, INC.	-15.98%	20.29B
UNITED THERAPEUTICS CORPORATION	+33.93%	12.78B
MEDPACE HOLDINGS, INC.	+28.84%	12.18B
BIO-TECHNE CORPORATION	-2.89%	11.96B

Other Biotechnology & Medical Research